Key Record Dates Identifier: NCT03075696
Brief Title: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

First Submitted : March 7, 2017
First Submitted that Met QC Criteria : March 7, 2017
First Posted : March 9, 2017

Last Update Submitted that Met QC Criteria : October 28, 2021
Last Update Posted : November 1, 2021